Bicycle therapeutics plc (BCYC)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Collaboration revenues

1,129

5,281

614

1,522

6,384

1,057

1,610

1,661

2,808

Operating expenses:
Research and development

7,774

6,649

6,078

6,537

6,276

-

5,642

4,917

-

General and administrative

4,998

3,396

4,789

2,973

3,402

-

2,325

1,702

-

Total operating expenses

12,772

10,045

10,867

9,510

9,678

8,599

7,967

6,619

5,697

Loss from operations

-11,643

-4,764

-10,253

-7,988

-3,294

-

-6,357

-4,958

-

Other income (expense):
Interest and other income

212

220

440

90

64

-

26

52

-

Other expense, net

-

0

0

-2,184

-3,193

-

-1,361

-73

-

Total other income (expense), net

212

220

440

-2,094

-3,129

901

-1,335

-21

-41

Net loss before income tax provision

-11,431

-4,544

-9,813

-10,082

-6,423

-6,641

-7,692

-4,979

-2,930

(Benefit from) provision for income taxes

-107

-138

-331

135

80

0

0

0

-396

Net loss

-11,324

-4,406

-9,482

-10,217

-6,503

-6,641

-7,692

-4,979

-2,534

Net loss attributable to ordinary shareholders

-11,324

-4,406

-9,482

-10,217

-6,503

-

-7,692

-4,979

-

Net loss per share attributable to ordinary shareholders, basic and diluted

-0.63

-0.25

-0.53

-1.40

-7.80

-13.19

-17.73

-11.85

-6.38

Weighted average ordinary shares outstanding, basic and diluted

17,997

17,926

17,900

7,298

834

503

433

420

397

Comprehensives Loss:
Net loss

-11,324

-4,406

-9,482

-10,217

-6,503

-6,641

-7,692

-4,979

-2,534

Other comprehensive income (loss):
Foreign currency translation adjustment

-2,184

1,072

-424

-1,512

1,080

-

-537

-2,657

-

Total comprehensive loss

-13,508

-3,334

-9,906

-11,729

-5,423

-

-8,229

-7,636

-